CIK 0001689375
- Accelerated filer
- Smaller reporting company
- Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813983399
- Phone
- +1 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- 4 Shares withheld for taxes Chief Financial Officer gave up 2,215 shares (to pay taxes)
- 4 Shares withheld for taxes President & COO gave up 2,238 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 2,266 shares (to pay taxes)
- 4 Planned sale CEO sold 1,000 shares at $15.00 ($15,000)
- 4 Planned sale CEO sold 1,000 shares at $15.99 ($15,990)
- 4 Planned sale Chief Financial Officer sold 12,500 shares at an average $15.59 ($194,845)
- 4 Planned sale President and CEO sold 1,000 shares at $15.00 ($15,000)
- 4 Planned sale President and CEO sold 1,000 shares at $16.23 ($16,230)
- 4 Planned sale President and CEO sold 1,000 shares at $15.00 ($15,000)
- 4 Planned sale President and CEO sold 1,000 shares at $15.00 ($15,000)
- 4 Shares withheld for taxes President and CEO gave up 1,440 shares (to pay taxes)
- 4 Planned sale Chief Financial Officer sold 950 shares at an average $13.48 ($12,806)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 449 shares (to pay taxes)
- 4 Planned sale Chief Medical Officer sold 892 shares at an average $13.48 ($12,022)
- 4 Planned sale Chief Operating Officer sold 972 shares at an average $13.47 ($13,089)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Planned sale President and CEO sold 1,000 shares at $15.67 ($15,671)
- 4 Planned sale Chief Medical Officer sold 26,710 shares at an average $14.76 ($394,219)
- 4 Planned sale Chief Financial Officer sold 10,000 shares at an average $17.99 ($179,862)
Page 6 of 13 · 242 filings